CSTL

CSTL

USD

Castle Biosciences Inc. Common Stock

$19.270-0.030 (-0.155%)

リアルタイム価格

Healthcare
Diagnostics & Research
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$19.300

高値

$19.800

安値

$19.070

出来高

0.10M

企業ファンダメンタルズ

時価総額

555.8M

業種

Diagnostics & Research

United States

取引統計

平均出来高

0.42M

取引所

NGM

通貨

USD

52週レンジ

安値 $16.965現在値 $19.270高値 $35.84

AI分析レポート

最終更新: 2025年4月28日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

CSTL (Castle Biosciences Inc. Common Stock): What's Happening and What to Watch

Stock Symbol: CSTL Generate Date: 2025-04-28 16:06:14

Let's break down what's been going on with Castle Biosciences and what the recent information might suggest. Think of this as getting the lowdown on the stock's recent activity and potential next steps.

The Latest Buzz (News Vibe)

Looking at the recent news headlines, the general feeling around Castle Biosciences seems pretty positive right now.

Why? Well, one big piece of news highlighted new data for their DecisionDx-Melanoma test at a major medical meeting (AACR). This is a good sign because it shows they're getting their key products in front of important audiences and demonstrating their value, specifically for identifying high-risk melanoma patients early on. That kind of visibility and validation can be a real boost.

They also announced when they'll release their first-quarter financial results – that's set for May 5th. This isn't positive or negative news itself, but it's a date everyone interested in the stock will mark on their calendar. The actual results will be the important part then.

Plus, the company got recognized as a "Top Workplaces USA" for the fourth year running. While not directly about sales or profits, it speaks well to the company culture and stability, which can be a quiet positive for investors.

So, overall, the news flow lately has a definite upward lean, driven by product data and positive company recognition.

Checking the Price Chart (What the Stock's Been Doing)

Now, let's look at the stock price itself over the last month or so. The chart tells a story of a significant dip followed by a recent recovery.

Back in late January and early February, the stock was trading comfortably in the $27-$28 range. Then, around late February and early March, it took a noticeable slide, dropping into the $19-$21 area. That was a pretty sharp move down.

However, since early April, things have looked better. The price seems to have found a floor and has been gradually climbing back up. It's been trading mostly between $19 and $21, and the trend in April has been generally positive, moving towards the upper end of that range.

Today, the stock closed around $20.05. This puts it right in the middle of that recent April trading range, but still well below where it was a couple of months ago.

Interestingly, an AI model that looks at stock predictions is quite bullish. It's predicting positive price moves for the next few days: +2.00% today (which has already happened to some extent, though the closing price is slightly below the previous day's close), +1.90% tomorrow, and +3.40% the day after. This AI forecast suggests the recent upward momentum could continue.

Putting It All Together (Outlook & Ideas)

Considering the positive news vibe, the recent price recovery on the chart, and the bullish AI prediction, the near-term picture for CSTL seems to lean positive.

The company is getting good press for its core product and its workplace culture, which creates a favorable backdrop. The stock price has shown resilience by bouncing back from its earlier lows. And the AI model is throwing out a strong signal for continued upward movement in the very short term.

What might this mean for potential action?

  • Apparent Leaning: Based on this combination, the situation seems to favor potential buyers looking at the near term, suggesting a possible 'buy' or 'accumulate' window if you're comfortable with the risks.
  • Potential Entry Consideration: The AI recommendation data mentioned potential entry points around $20.57 to $20.72, and a support level near $20.53. The current price ($20.05) is actually a bit below these levels. One way to approach this, based on the AI's bullish view, might be to watch if the stock can push back up and hold above that $20.50-$20.70 area. Getting above there could confirm the AI's bullish signal and the recent upward trend. Alternatively, some might see the current price slightly below that zone as a potentially better entry if they believe the AI's overall bullish forecast is correct.
  • Potential Exit/Stop-Loss Consideration: The AI model also gave some specific levels for managing risk and potential gains. It suggested a potential Take Profit level around $22.19. This could be a target to watch if the stock continues its climb. For managing downside risk, the AI suggested a Stop Loss at $18.56. Setting a stop loss below a recent low or a key support level like this is a common strategy to limit potential losses if the trend reverses unexpectedly.

A Little More Context

Remember, Castle Biosciences is in the Healthcare sector, specifically Diagnostics & Research. They make specialized tests, mainly for skin cancers and other conditions. So, news about their test performance and adoption, like the recent data presentation, is really central to their business prospects.

Also, the AI data pointed out that this is a company with a relatively small market capitalization (around $586 million). Smaller companies can sometimes see bigger price swings, both up and down, compared to larger, more established businesses. That's just something to keep in mind regarding the risk level.

Putting it all together, the recent news and AI forecast paint a positive picture for CSTL in the short term, following a period of price recovery. Watching how the stock interacts with the $20.50-$20.70 area and keeping the AI's suggested risk management levels in mind could be useful next steps for anyone considering this stock.


Disclaimer: This analysis is based on the provided data and is for informational purposes only. It is not financial advice. Stock investing involves risk, and you could lose money. Always do your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

関連ニュース

GlobeNewswire

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, "The Time is Now: A Clinical Practice Model to Help Prevent Progression

もっと見る
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
GlobeNewswire

New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines' 5% threshold to forgo sentinel

もっと見る
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
GlobeNewswire

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve

もっと見る
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
GlobeNewswire

Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its

もっと見る
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

AI予測Beta

AI推奨

強気

更新日時: 2025年5月2日 19:38

弱気中立強気

65.7% 信頼度

リスクと取引

リスクレベル3/5
中リスク
適しているのは
成長
取引ガイド

エントリーポイント

$19.39

利確

$19.70

損切り

$17.38

主要因子

DMIは弱気トレンドを示しており (ADX:21.0、+DI:6.8、-DI:11.8)、注意が必要です
現在の価格はサポートレベル(19.38ドル)に非常に接近しており、強力な買い機会を示唆しています
出来高は平均(4,601)の10.4倍で、極めて強い買い圧力を示しています
MACD -0.0576はシグナルライン-0.0568の下にあり、弱気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。